Navigation Links
Reduced intensity regimen prior to marrow transplant better for older leukemia patients
Date:12/9/2012

COLUMBUS, Ohio A new study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) shows that preparing older acute myeloid leukemia (AML) patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients. The study was presented at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

Typically, the prognosis for older AML patients is poor. Even in patients who achieve complete remission through chemotherapy, survival rates remain low due to high risk of relapse. While blood or bone marrow transplants can be a viable option for younger patients, conventional preparative regimens leading up to the procedure are often too toxic for patients over the age of 60.

"With a reduced intensity regimen leading up to a transplant, the disease free survival rate in older patients reached 39 percent," said Steven M. Devine, MD, Professor of Internal Medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, and director of the Blood and Marrow Transplant Program. "These outcomes are better than those achieved using more conventional treatments and warrant additional comparison research and studies focused on preventing relapse in this patient population."

Methodology & Results

The objective of the Phase II, prospective, multi-center trial was to determine the feasibility and effectiveness of a uniform reduced intensity conditioning regimen prior to a blood cell transplant in older AML patients in clinical remission. The primary endpoint of the study was two-year disease-free survival. Researchers hypothesized that disease-free survival at two years would exceed 20 percent. One hundred twenty three AML patients in first clinical remission following chemotherapy, ages 60-74, were transplanted at 21 centers across the country. Forty seven percent of patients had match related donors and 53 percent had unrelated donors. All but eight patients (who received fludarabine and busulfan alone) were conditioned with the same regimen containing fludarabine (30mg/m2/day x 5), busulfan (6.4mg/kg IV total dose) and antithymocyte globulin (7.5mg/kg total dose). One case of primary graft failure was reported. Rates of both acute and chronic graft vs host disease and treatment related mortality were relatively low. There were no unexpected toxicities associated with these transplants.. Relapse was the most common cause of death.


'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Huntingtons Disease Linked to Reduced Cancer Risk in Study
2. Decision guide reduced uncertainty over breast cancer prevention, study finds
3. Physical activity linked to reduced mortality in breast and colon cancer patients
4. High-contrast, high-resolution CT scans now possible at reduced dose
5. Long-term testosterone treatment for men results in reduced weight and waist size
6. HCOs find risks & opportunities in quest for reduced costs & improved quality
7. Health care organizations quest for reduced costs and improved quality
8. PharmaNet system dramatically reduced inappropriate prescriptions of potentially addictive drugs
9. Study shows anaesthetic-related deaths reduced dramatically
10. Health inequalities could be reduced by more effective healthcare, says new study
11. Health inequalities could be reduced by more effective health care, says new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Lehi, Utah (PRWEB) , ... January 17, 2017 ... ... provider of accredited, online continuing education for EMS and firefighting professionals, has released ... Training (VILT) Solution. These new courses are taught live in an online classroom ...
(Date:1/17/2017)... TEXAS (PRWEB) , ... January 17, 2017 , ... ... provider, today announced its partnership with Sigfox in the U.S.A. to ... cities nationwide including new offerings on large-scale environmental sensor deployments such as ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused ... study for its dental gel that shows significant reduction in plaque levels and gum ... The study was conducted at the Beckman Laser Institute at UC Irvine and has ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... private companies and ranked among the top US security companies for consecutive years, ... This announcement brings a year-long independent board nomination process to a close ...
(Date:1/16/2017)... ... January 17, 2017 , ... ... an internationally recognized leader in the fast-casual category, announces a hearty and wholesome ... Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 EU5 Glucose Monitoring Market ... report, "EU5 Glucose Monitoring Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segments - Blood Glucose Meters, Blood Glucose Test Strips ... and distribution shares data for each of these market ...
(Date:1/17/2017)... Jan. 17, 2017 Paragon Bioservices received a ... development services for a variety of National ... medical product development activities. The IDIQ mechanism will ... for task order awards up to $159 million. ... manufacturing and process development of biopharmaceuticals, is one ...
(Date:1/17/2017)... 2017  Pennsylvania Secretary of Health Dr. ... marijuana growers/processors and dispensaries are now available on ... Permit applications will be accepted from February 20 ... an important step forward in getting this valuable ... Murphy said. "We,ve developed a thorough application that ...
Breaking Medicine Technology: